WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406725
Description: KRN383 also inhibited the proliferation of the ITD-positive cell lines with IC(50) values of < or =2.9 nM. A single oral administration of 80 mg/kg of KRN383 eradicated ITD-positive xenograft tumors in nude mice and prolonged the survival of SCID mice carrying ITD-positive AML cells. The effectiveness of a single oral dose of KRN383 suggests that it has the potential to be used in a wide variety of clinical regimens, including multicycle and combination therapies.
MedKoo Cat#: 406725
Chemical Formula: C17H17N3O4
Exact Mass: 327.12191
Molecular Weight: 327.33
Elemental Analysis: C, 62.38; H, 5.23; N, 12.84; O, 19.55
KRN383 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: KRN383, KRN 383, KRN-383
IUPAC/Chemical Name: 1-(4-((7-hydroxy-6-methoxyquinolin-4-yl)oxy)cyclohexa-1,5-dien-1-yl)urea
InChi Key: FDEJMZJEHJWMRY-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H17N3O4/c1-23-16-8-12-13(9-14(16)21)19-7-6-15(12)24-11-4-2-10(3-5-11)20-17(18)22/h2-4,6-9,11,21H,5H2,1H3,(H3,18,20,22)
SMILES Code: O=C(N)NC1=CCC(OC2=CC=NC3=CC(O)=C(OC)C=C23)C=C1
The following data is based on the product molecular weight 327.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Giles FJ. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting. Leuk Res. 2006 Dec;30(12):1469-70. Epub 2006 May 2. PubMed PMID: 16631251.
2: Nishiyama U, Yoshino T, Ozai M, Yoshioka R, Fujisawa M, Ogasawara Y, Kitahori M, Yoshioka E, Kubo K, Komeno Y, Kurokawa M, Ogawa S, Chiba S, Osawa T, Kuwaki T, Hirai H, Miwa A. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations. Leuk Res. 2006 Dec;30(12):1541-6. Epub 2006 Apr 17. Erratum in: Leuk Res. 2007 Oct;31(10):1457. PubMed PMID: 16603240.